Drug intelligence / Profile preview

LC542019

Development stage: Phase 1
Lead developer: LG Chem
Modality: Small Molecules
Administration: Oral

Overview

LC542019 is an investigational small molecule drug developed by LG Chem for the treatment of type 2 diabetes. Its mechanism of action involves activating GPR120 (also known as free fatty acid receptor 4), a protein that regulates insulin sensitivity. By acting as a GPR120 agonist, LC542019 aims to improve insulin resistance, thereby facilitating glucose uptake into cells and lowering blood sugar levels. Preclinical studies have also suggested potential benefits in weight loss and improvement of fatty liver. The drug is administered orally and has completed phase 1 clinical trials in the United States, where it was evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy adults and patients with type 2 diabetes.

Other names: LC-542019LC542019LC 542019

Targets

FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on LC542019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC542019.

Explore the full profile